- Home
- FUBO vs RIGL Comparison
FUBO vs RIGL Comparison
Compare FUBO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUBO
- RIGL
- Stock Information
- Founded
- FUBO 2009
- RIGL 1996
- Country
- FUBO United States
- RIGL United States
- Employees
- FUBO N/A
- RIGL N/A
- Industry
- FUBO Broadcasting
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- FUBO Industrials
- RIGL Health Care
- Exchange
- FUBO Nasdaq
- RIGL Nasdaq
- Market Cap
- FUBO 534.5M
- RIGL 486.4M
- IPO Year
- FUBO 2020
- RIGL 2000
- Fundamental
- Price
- FUBO $1.37
- RIGL $17.09
- Analyst Decision
- FUBO Buy
- RIGL Buy
- Analyst Count
- FUBO 6
- RIGL 5
- Target Price
- FUBO $2.88
- RIGL $34.80
- AVG Volume (30 Days)
- FUBO 14.4M
- RIGL 203.8K
- Earning Date
- FUBO 11-01-2024
- RIGL 11-07-2024
- Dividend Yield
- FUBO N/A
- RIGL N/A
- EPS Growth
- FUBO N/A
- RIGL N/A
- EPS
- FUBO N/A
- RIGL 0.22
- Revenue
- FUBO $1,589,700,000.00
- RIGL $157,374,000.00
- Revenue This Year
- FUBO $21.18
- RIGL $48.98
- Revenue Next Year
- FUBO $11.64
- RIGL $14.43
- P/E Ratio
- FUBO N/A
- RIGL $77.18
- Revenue Growth
- FUBO 24.45
- RIGL 21.65
- 52 Week Low
- FUBO $1.10
- RIGL $7.48
- 52 Week High
- FUBO $3.43
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- FUBO 38.75
- RIGL 30.82
- Support Level
- FUBO $1.66
- RIGL $16.68
- Resistance Level
- FUBO $1.83
- RIGL $19.80
- Average True Range (ATR)
- FUBO 0.11
- RIGL 1.53
- MACD
- FUBO -0.04
- RIGL -1.05
- Stochastic Oscillator
- FUBO 17.12
- RIGL 3.66
About FUBO fuboTV Inc.
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segment of the group is Streaming. It has a business presence in the United States and other international countries.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.